BRCA Somatic
Genetic Testing for BRCA Somatic
Patients who test positive for mutations in the BRCA1 and BRCA2 genes are identified by the BRCA somatic test, which may help them benefit from PARP inhibitor treatment.Because they code for tumor suppressor proteins, these genes are crucial for DNA repair. Because they code for proteins that inhibit tumor growth, these genes are crucial.Genetic testing for BRCA1 and BRCA2 mutations aids in treatment selection.PARP inhibitors impede the proliferation of cancer cells harboring BRCA1 or BRCA2 gene mutations. They zero in on Poly(ADP)Ribose Polymerases (PARP), enzymes that are vital for DNA repair. Biomarkers of patient response to PARP inhibitors include somatic BRCA gene mutations in advanced ovarian and prostate cancer patients.
Those who are thought to need this exam are those who have:
- Detailed medical background including breast and ovarian cancers,
- Background information regarding prostate cancer
- Background information regarding the pancreas and/or peritoneum
- Details on the BRCA Somatic Cell Assay
Thermo Fisher Scientific’s Ion Proton Next Generation Sequencing platform is used to conduct the Oncomine BRCA assay, which is used in the BRCA Somatic test. This platform offers:
High level of certainty in identifying somatic mutations (>99%)
<2% Rate of Failure
Unmatched Sensitivity
Valuation for Predictions > 99.3 percent
Depth of coverage > 1000
Report on BRCA somatic sample
This screening looks for BRCA somatic mutations, which have been found in a number of solid malignancies, including prostate, ovarian, pancreatic, and breast cancers.
Additionally, BRCA Somatic can identify tumor-specific mutations, commonly known as somatic mutations. As a result, more patients with a detectable BRCA mutation may be able to benefit from PARP inhibitor treatment. It is advised to analyze genomic DNA from the patient’s blood if a harmful mutation is found; this will help identify if the mutation is inherited or somatic.
It is advised to conduct genomic DNA analysis on the patient’s blood if a harmful mutation is found; this will help identify if the mutation is inherited or somatic. It is also recommended to analyze the patient’s relatives for the specific mutation if it is a germline mutation.
It is advised to conduct the BRCA Germline test or the HereditaryGENE test if a hereditary syndrome is suspected.
After 15 business days, you will be able to view the results.
Either tumor tissue preserved in paraffin or unstained paraffin slides that have not been autoclaved. To be more precise, we require four 3μm portions and six 10μm sections.
Bank transfer
Emails are sent to your primary care physician with your results.
If you have any queries about the services provided by Scipharm, our customer care team is here to help. Get in touch with us personally if you’re interested in ordering any of Scipharm’s tests.
